Jane Street Group, LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Jane Street Group, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	SELL	$5.46 - $8.29 $156,702 - $237,922	-28,700 Reduced 66.59%	14,400 $98,000
Q4 2021 Feb 15, 2022	SELL	$7.34 - $11.18 $65,326 - $99,502	-8,900 Reduced 17.12%	43,100 $348,000
Q3 2021 Nov 16, 2021	BUY	$6.49 - $9.91 $200,541 - $306,219	30,900 Added 146.45%	52,000 $510,000
Q1 2021 May 18, 2021	BUY	$6.61 - $10.07 $139,471 - $212,477	21,100 New	21,100 $191,000
Q3 2020 Nov 17, 2020	SELL	$5.02 - $8.98 $58,733 - $105,066	-11,700 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$7.25 - $11.75 $84,825 - $137,475	11,700 New	11,700 $95,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $478M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.